RecruitingNCT06575075
Testing two HNK doses for obsessive-compulsive symptoms
About this title
Read the official source — NCT06575075Medication studyAges 18–65United StatesOCD
Understand this study
Who could participate?
This study is for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
You receive one IV infusion of RR-HNK at 0.25 or 0.5 mg/kg, or a sterile-saline placebo (an inactive comparison treatment), depending on your assigned group. EEG (recording of the brain’s electrical activity) and computer-based behavioural tests are done before and after the infusion; symptom change is assessed through one week.
- Listed locations
- Palo AltoSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 23, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 45
- Sponsor
- Carolyn Rodriguez
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06575075
- Official title
Show the full official title
A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Palo Alto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Carolyn Rodriguez.
Does this study involve medication?
Yes. The study involves medication, including RR-HNK/Hydroxynorketamine and Placebo.
Who can participate?
This study is for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
